Meglitinides

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide

Top

Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. ACC Abstracts of the 48th Scientific Session. 2009;32(5):409-418. Hypoglycaemia is an acute complication associated with intensive treatment of patients with diabetes mellitus. This complication poses a major challenge in diabetes management. 

Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin

Top

Derosa G, D'Angelo A, Fogari E, et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther. 2009;34(1):13-23. Most antidiabetic agents target only one of several underlying causes of diabetes. The complementary actions of the glinides and the biguanides may give optimal glycemic control in patients with type 2 diabetes mellitus.

Prevention of diabetes & cardiovascular disease in patients w/ impaired glucose tolerance: rationale & design of Nateglinide & Valsartan

Top

Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623-632. Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle modification and medication can prevent or delay progression to diabetes (PD), but whether such interventions also reduce the risk of CVD has not been rigorously tested.

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus

Top

Campbell IW. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract. 2005;59:1218-1228. Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial glucose levels. Nateglinide, a d-phenylalanine derivative, restores postprandial early phase insulin secretion in a transient and glucose-sensitive manner without affecting basal insulin levels.

Pharmacologic prevention or delay of type 2 diabetes mellitus

Top

Anderson DC, Jr. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother. 2005;39:102-109. To evaluate the current data on pharmacologic interventions intended to prevent or delay the onset of type 2 diabetes mellitus.

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes

Top

Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2004;20:883-889. OBJECTIVE: To assess the efficacy and tolerability of the combination of nateglinide (120 mg, ac) and metformin (500 mg, tid) as initial treatment in drug-naive patients with type 2 diabetes mellitus (T2DM).

Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes

Top

Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes. Diabetes Care.2002;25:1529-1533. OBJECTIVE-To compare the effects of monotherapy using nateglinide and the thiazolidinedione troglitazone with initial combination of the two agents on glycated hemoglobin in patients with type 2 diabetes inadequately controlled by diet alone.

Nateglinide Alone and in Combination With Metformin Improves Glycemic Control by Reducing Mealtime Glucose Levels in Type 2 Diabetes

Top

Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide Alone and in Combination With Metformin Improves Glycemic Control by Reducing Mealtime Glucose Levels in Type 2 Diabetes. Diabetes Care. 2000;23:1660-1665. To evaluate the efficacy and tolerability of nateglinide and metformin alone and in combination in type 2 diabetic patients inadequately controlled by diet, focusing on changes in HbA1c, fasting plasma glucose (FPG), and mealtime glucose excursions.

Synergistic Effects of Nateglinide and Meal Administration on Insulin Secretion in Patients With Type 2 Diabetes

Top

Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF. Synergistic Effects of Nateglinide and Meal Administration on Insulin Secretion in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2000;85:1081-1086. This study assessed the synergistic effects of nateglinide (a nonsulfonylurea D-phenylalanine derivative) and meals on insulin secretion in 24 patients with type 2 diabetes.